No Data
No Data
Why BioXcel Therapeutics, Inc. (BTAI) Soared Last Week
BioXcel Therapeutics Climbs After Enrollment Update in Drug Trial
BioXcel Therapeutics Shares Are Trading Higher After the Company Announced It Has Reached 33% Enrollment in Its 200-patient SERENITY At-Home Trial.
Express News | BioXcel Therapeutics Inc: Topline Data Expected in Second Half of 2025
Express News | BioXcel Therapeutics Announces 33% Enrollment in Serenity at-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated With Bipolar Disorders or Schizophrenia
BioXcel Therapeutics, Inc. (BTAI) May Report Negative Earnings: Know the Trend Ahead of Q4 Release